In this issue of the I MJA i , White and his colleagues[8] report a trial of routine antenatal anti-D prophylaxis (RAADP) that compared the outcomes of single and two-dose regimens. It is important to note that the evidence for the benefits and risks of anti-D prophylaxis is soundly based on studies of the combination of antenatal and post-delivery prophylaxis.